Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy
Închide
Căutare avansată
Site Map
Conţinutul numărului revistei
Articolul precedent
Articolul urmator
390 2
Ultima descărcare din IBN:
2022-08-17 11:45
SM ISO690:2012
YURDAYDIN, Cihan, ABBAS, Zaigham, BUTI, Maria Asuncion, CORNBERG, Markus, ESTEBAN, Rafael, ETZION, Ohad, GANE, Edward John, GISH, Robert G., GLENN, Jeffrey S., HAMID, Saeed Sadiq, HELLER, Theo, KOH, Christopher, LAMPERTICO, Pietro, LURIE, Yoav, MANNS, Michael Peter, PARANA, Raymundo, RIZZETTO, Mario, URBAN, Stephan, WEDEMEYER, Heiner Heinrich, WRANKE, Anika, BORZACOV, L.M.Pinheiro, LOBATO, Cirley Maria De Oliveira, CEAUSU, Emanoil, DALEKOS, George Nikolaos, ŢURCANU, Adela, NIRO, Grazia Anna, LUBNA, Farheen, ABBAS, Mohamed Khaddouj Awada, INGILIZ, Patrick, FERENCI, Peter, VANWOLLEGHEM, Thomas, MIXSON-HAYDEN, Tonya R., DASHDORJ, Naranjargal, MOTOC, Adriana, HARDTKE, Svenja. Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. In: Journal of Hepatology, 2019, nr. 5(70), pp. 1008-1015. ISSN 0168-8278. DOI: https://doi.org/10.1016/j.jhep.2018.12.022
EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core
Journal of Hepatology
Numărul 5(70) / 2019 / ISSN 0168-8278 /ISSNe 1600-0641

Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy
DOI:https://doi.org/10.1016/j.jhep.2018.12.022

Pag. 1008-1015

Yurdaydin Cihan1, Abbas Zaigham2, Buti Maria Asuncion3, Cornberg Markus4, Esteban Rafael3, Etzion Ohad5, Gane Edward John6, Gish Robert G.7, Glenn Jeffrey S.7, Hamid Saeed Sadiq, Heller Theo8, Koh Christopher8, Lampertico Pietro9, Lurie Yoav10, Manns Michael Peter4, Parana Raymundo11, Rizzetto Mario12, Urban Stephan13, Wedemeyer Heiner Heinrich4, Wranke Anika14, Borzacov L.M.Pinheiro15, Lobato Cirley Maria De Oliveira16, Ceausu Emanoil17, Dalekos George Nikolaos18, Ţurcanu Adela19, Niro Grazia Anna20, Lubna Farheen21, Abbas Mohamed Khaddouj Awada19, Ingiliz Patrick22, Ferenci Peter23, Vanwolleghem Thomas24, Mixson-Hayden Tonya R.25, Dashdorj Naranjargal26, Motoc Adriana17, Hardtke Svenja27
 
1 Ankara University, Turkey,
2 Sindh Institute of Urology and Transplantation, Karachi,
3 Hospital Vall d’Hebron,
4 Hannover Medical School,
5 Ben-Gurion University,
6 University of Auckland,
7 Stanford University Medical Center, Stanford,
8 National Institutes of Health, Bethesda,
9 University of Milan,
10 Israel Ministry of Health,
11 Universidade Federal da Bahia,
12 University of Torino,
13 University Hospital Heidelberg,
14 Gastroenterology, Hepatology and Endocrinology, Hannover Medical School,
15 Federal University of Rondonia,
16 Spitalul das Clínicas do Acre,
17 Victor Babes Clinical Hospital for Infectious and Tropical Diseases, Infectious Diseases, Bucharest,
18 University of Thessaly,
19 ”Nicolae Testemițanu” State University of Medicine and Pharmacy,
20 Regional General Hospital “Casa Relief of Suffering”, Division of Gastroenterology, San Giovanni Rotondo,
21 Aga Khan University, Karachi,
22 Center for Infectiology Berlin (CIB),
23 Medical University of Vienna,
24 Antwerp University Hospital, Edegem,
25 Center for Disease Control and Prevention, Atlanta,
26 University of Nottingham,
27 German Centre for Infection Research (DZIF), Partner Site Hamburg-Luebeck-Borstel-Riems
 
 
Disponibil în IBN: 22 aprilie 2021
Rezumat

Chronic hepatitis delta represents the most severe form of chronic viral hepatitis. The current treatment of hepatitis delta virus (HDV) infection consists of the use of interferons and is largely unsatisfactory. Several new compounds are currently in development for the treatment of HDV infection. However, surrogate markers that can be used to develop clinical endpoints in HDV infection are not well defined. In the current manuscript, we aimed to evaluate the existing data on treatment of HDV infection and to suggest treatment goals (possible “trial endpoints”) that could be used across different clinical trials.
Cuvinte-cheie
BiomarkersClinical Trials as Topic, Hepatitis B Surface Antigens, hepatitis D, chronic, Humans, Lipopeptides, liver, Nucleic Acids, Piperidines, PolymersPyridinesRNA, ViralTreatment Outcome

Share

Institutul de Dezvoltare a Societatii InformationaleEXPERT on-lineInstitutul de Dezvoltare a Societatii InformationaleCN-2022Indicatori CDIASM

CC-BY-NC

Copyright © 2012 - 2024 Instrument Bibliometric National

Institutul de Dezvoltare a Societatii Informationale All Rights Reserved.

IBN v1.5.5

CSS valid!